title: Initial drug treatment in Parkinson's disease.
authors.affiliation: School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK University Hospital Birmingham Foundation Trust, Queen Elizabeth Hospital, Birmingham shammuzerengi@yahoo.com.
authors.forename: Sharon
authors.initials: S
authors.lastname: Muzerengi
authors.affiliation: School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Birmingham.
authors.forename: Carl E
authors.initials: CE
authors.lastname: Clarke
mesh_terms: D000978:Antiparkinson Agents / Q000008:administration & dosage*; D003362:Cost-Benefit Analysis; D018491:Dopamine Agonists / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; D007980:Levodopa